March 4 (Reuters) - Bristol-Myers Squibb Co:
* Says could seek approval this year for melanoma drug ipilimumab
* Says moving forward with phase 3 study of ipilimumab in non-small cell lung
cancer
* Says planning to seek approval this year for sprycel in first-line chronic
myeloid leukemia
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Says could seek approval this year for melanoma drug ipilimumab
* Says moving forward with phase 3 study of ipilimumab in non-small cell lung
cancer
* Says planning to seek approval this year for sprycel in first-line chronic
myeloid leukemia
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
